…
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Rafael Holdings, Inc. (RFL) is limited; the company is described in public filings as a small, publicly traded holding company with interests in operating assets. Long-term growth may depend on management’s ability to acquire or improve portfolio companies and on successful execution of strategic transactions, which could support value appreciation for shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Income before tax | -33.20M | -67.68M | -8.74M | -139.97M | -25.13M |
| Minority interest | - | 30.59M | 0.34M | 17.72M | 14.42M |
| Net income | -30.52M | -34.41M | -1.88M | -124.66M | -25.15M |
| Selling general administrative | 13.78M | 8.85M | 8.93M | 16.98M | 20.42M |
| Gross profit | 0.49M | 0.48M | 0.28M | 0.41M | 3.97M |
| Reconciled depreciation | - | 0.23M | 0.08M | 0.07M | 1.46M |
| Ebit | -32.54M | -67.01M | -17.59M | 19.17M | -29.81M |
| Ebitda | -32.25M | -66.79M | -17.51M | 19.24M | -19.11M |
| Depreciation and amortization | 0.29M | 0.23M | 0.08M | 0.07M | 10.70M |
| Operating income | -26.11M | -102.63M | -15.04M | 19.17M | -29.81M |
| Other operating expenses | 27.03M | 103.26M | 15.32M | 60.89M | 26.78M |
| Interest expense | 0.66M | 0.25M | 0.00M | 0.01M | 0.10M |
| Tax provision | -2.55M | -2.68M | -0.26M | 0.00M | 0.02M |
| Interest income | 4.35M | 2.38M | 3.25M | 0.20M | 4.66M |
| Net interest income | - | 2.13M | 3.25M | 0.20M | -0.10M |
| Extraordinary items | - | 0.00M | 6.48M | -1.83M | -1.71M |
| Income tax expense | -2.55M | -2.68M | -0.26M | -15.31M | 0.02M |
| Total revenue | 0.92M | 0.64M | 0.28M | 0.41M | 3.97M |
| Total operating expenses | 26.60M | 103.11M | 15.32M | 60.89M | 26.78M |
| Cost of revenue | 0.42M | 0.15M | - | - | - |
| Total other income expense net | -7.09M | 34.94M | 6.30M | -159.14M | 4.68M |
| Discontinued operations | - | - | - | -1.83M | -1.71M |
| Net income from continuing ops | - | -65.00M | -8.69M | -140.55M | -24.77M |
| Net income applicable to common shares | -30.52M | -34.41M | -1.88M | -124.66M | -24.54M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Total assets | 114.11M | 96.83M | 98.83M | 118.32M | 154.06M |
| Intangible assets | 32.57M | 1.85M | 1.57M | 1.57M | 1.57M |
| Other current assets | 1.83M | 0.43M | 0.91M | 44.81M | 1.07M |
| Total liab | 15.74M | 10.57M | 2.20M | 21.11M | 17.35M |
| Total stockholder equity | 94.39M | 82.19M | 100.29M | 100.52M | 122.29M |
| Deferred long term liab | - | - | - | 1.57M | 1.57M |
| Other current liab | 4.09M | 2.64M | 1.81M | 5.46M | 0.25M |
| Common stock | 0.52M | 0.25M | 0.24M | 0.24M | 0.18M |
| Capital stock | - | 0.25M | 0.24M | 0.24M | 0.18M |
| Retained earnings | -232.26M | -201.74M | -167.33M | -165.46M | -40.80M |
| Other liab | - | - | - | 0.09M | 0.05M |
| Good will | 19.94M | 3.05M | - | - | - |
| Other assets | 1.43M | 0.04M | 0.01M | 2.96M | 10.59M |
| Cash | 52.77M | 2.67M | 21.50M | 26.54M | 7.85M |
| Cash and equivalents | 52.77M | 2.67M | 21.50M | 26.54M | 7.85M |
| Total current liabilities | 11.60M | 7.51M | 2.15M | 21.03M | 17.30M |
| Current deferred revenue | - | - | - | - | 1.36M |
| Net debt | -52.08M | -0.29M | -21.50M | -11.54M | 6.67M |
| Short term debt | 0.61M | 2.31M | 0.00M | 15.00M | 14.53M |
| Short long term debt | - | 2.31M | - | 15.00M | 14.53M |
| Short long term debt total | 0.69M | 2.39M | - | 15.00M | 14.53M |
| Other stockholder equity | 321.99M | 283.57M | 264.01M | 262.02M | 159.14M |
| Property plant equipment | 1.60M | 2.12M | 1.70M | 1.77M | 43.24M |
| Total current assets | 56.71M | 72.50M | 82.94M | 108.35M | 14.76M |
| Long term investments | - | 12.01M | 7.62M | 0.48M | 80.19M |
| Net tangible assets | - | - | - | 100.52M | 122.29M |
| Short term investments | 0.00M | 63.27M | 58.01M | 36.70M | 0.57M |
| Net receivables | 1.83M | 6.13M | 2.52M | 0.30M | 0.83M |
| Long term debt | 0.08M | 0.07M | - | - | - |
| Inventory | 0.28M | - | - | - | 5.00M |
| Accounts payable | 6.89M | 2.56M | 0.33M | 0.56M | 1.16M |
| Accumulated other comprehensive income | 4.14M | 0.11M | 3.37M | 3.70M | 3.77M |
| Common stock total equity | - | - | - | - | 0.18M |
| Non currrent assets other | 1.43M | 5.30M | 0.01M | 6.15M | 1.52M |
| Non current assets total | 57.39M | 24.33M | 15.89M | 9.97M | 139.29M |
| Long term debt total | 0.08M | 0.07M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Investments | - | -10.82M | 21.21M | -36.81M | -8.17M |
| Change to liabilities | - | - | - | 0.05M | 0.16M |
| Total cashflows from investing activities | 44.03M | -10.82M | 21.21M | -63.80M | -8.17M |
| Net borrowings | - | -0.80M | - | - | 15.00M |
| Total cash from financing activities | 24.83M | -0.18M | -15.22M | 103.86M | 30.30M |
| Change to operating activities | - | - | - | -0.14M | -0.99M |
| Net income | -30.64M | -65.00M | -2.21M | -140.55M | -24.77M |
| Change in cash | 50.09M | -18.82M | -5.04M | 13.68M | 6.65M |
| Begin period cash flow | 2.67M | 21.50M | 26.54M | 12.85M | 6.21M |
| End period cash flow | 52.77M | 2.67M | 21.50M | 26.54M | 12.85M |
| Total cash from operating activities | -18.92M | -7.80M | -10.89M | -26.08M | -15.60M |
| Issuance of capital stock | - | - | 0.00M | 110.17M | 13.00M |
| Depreciation | 0.29M | 0.23M | 0.08M | 0.07M | 1.46M |
| Other cashflows from investing activities | -19.67M | -6.75M | 21.21M | -26.99M | -0.50M |
| Change to inventory | -0.01M | - | - | - | -1.13M |
| Change to account receivables | 0.09M | -0.29M | -0.12M | 0.07M | -0.16M |
| Sale purchase of stock | 25.00M | -0.17M | 0.00M | 110.17M | 15.07M |
| Other cashflows from financing activities | -0.22M | 0.79M | -15.22M | -6.30M | 17.30M |
| Change to netincome | - | - | - | 98.52M | 8.44M |
| Capital expenditures | 0.00M | 0.18M | 51.68M | 0.00M | 0.21M |
| Change in working capital | 0.97M | -0.61M | -0.09M | -0.01M | -0.99M |
| Stock based compensation | 2.12M | 2.30M | 2.19M | -0.92M | 8.66M |
| Other non cash items | 8.51M | 55.29M | -11.79M | 115.32M | 0.03M |
| Free cash flow | -18.93M | -7.98M | 40.79M | -26.08M | -15.81M |
Sector: Real Estate Industry: Real Estate Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RFL Rafael Holdings, Inc. |
0.02 2.19% |
0.92 | - | - | 113.55 | 1.50 | 85.18 | 5.39 |
| CBRE CBRE Group Inc Class A |
-1.55 1.21% |
126.77 | 38.92 | 21.37 | 1.09 | 4.95 | 1.28 | 25.73 |
| BEKE Ke Holdings Inc |
0.07 0.39% |
17.87 | 42.90 | 16.92 | 0.33 | 2.33 | 1.66 | 24.07 |
| VNNVF Vonovia SE |
-0.34 1.81% |
18.20 | - | 13.44 | 3.96 | 0.83 | 4.07 | -3.05 |
| VTAGY Vantage Towers AG |
- -% |
21.42 | 42.00 | 37.59 | 28.32 | 3.61 | 21.19 | 24.26 |
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Howard S. Jonas | Founder & Chairman | 1956 |
| Mr. William Conkling | Chief Exec. Officer | 1972 |
| Mr. Patrick Fabbio M.B.A. | CFO & Pres | 1968 |
| Ms. Barbara A. Ryan | Investor Relations Officer | 1960 |
| Mr. David A. Polinsky Esq. | Chief of Staff | 1972 |
| Mr. Gus Kodersha | Chief Technical Operations Officer | NA |
| Dr. Rick Ewing | Head of Drug Discovery | NA |
| Ms. Joyce J. Mason Esq. | Corp. Sec. | 1959 |
| Mr. Howard S. Jonas | CEO, President, Founder & Executive Chairman | 1956 |
| Mr. David A. Polinsky Esq. | Chief Financial Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.